FMC Corporation Earnings Call Transcripts
Fiscal Year 2026
-
Management is pursuing both independent growth and strategic alternatives, with strong interest in its new technology pipeline. Debt refinancing and licensing of new molecules are on track, while product strategies focus on volume growth and cost reduction. Geopolitical risks are being monitored, especially for logistics and raw material costs.
-
Management is executing a dual-path strategy: a 2026 operational plan with asset sales, manufacturing shifts, and new product growth, while also exploring broader strategic alternatives. Cost reductions, licensing deals, and innovation initiatives are underway to restore competitiveness and improve financial flexibility.
Fiscal Year 2025
-
Q4 2025 saw sales and EBITDA decline amid intense generic competition and weak grower margins, with 2026 guidance reflecting continued headwinds but growth expected from new active ingredients. The board is exploring strategic alternatives, including a potential sale, while targeting $1 billion in debt reduction.
-
Leadership outlined a shift from a soft-landing approach to a more aggressive transformation, focusing on cost competitiveness, balance sheet improvement, and strategic licensing. 2026 will be a year of deep change, with benefits expected in 2027 and new product growth by 2028.
-
Third quarter results were impacted by credit constraints and generic competition, with sales down sharply due to India-related actions. Adjusted EBITDA and EPS improved year-over-year, but full-year guidance was lowered and free cash flow remains negative. Major cost reductions, manufacturing changes, and a dividend cut are underway to address ongoing challenges.
-
Normalized but soft demand is expected to continue, with strong visibility for 2026. Growth is driven by new active ingredients and biologicals, while regulatory and regional strategies are adapting to market complexities. Nine new products are set to secure long-term growth.
-
Q2 results exceeded guidance with 1% sales growth and 2% higher adjusted EBITDA year-over-year, driven by strong growth in new actives and cost savings. The India commercial business will be divested, with guidance now excluding India, and 2027 EBITDA targets remain intact at $1.2 billion.
-
Leadership executed a strategic reset, positioning for growth with a robust product pipeline and new market entries. Financial guidance is on track, cost savings are realized, and collaborations with major industry players are set to accelerate expansion. Rynaxypyr risk is contained, while new products and regions drive optimism.
-
Reset and growth plans are on track, with new products like Fluindapyr and Isoflex driving H2 growth. Rynaxypyr's post-patent strategy focuses on cost reduction and new technologies, aiming to maintain profit levels. Receivables and tariffs are managed, and leadership is confident in the roadmap.
-
Q1 results met expectations: sales down 14%, EBITDA down 25% YoY. Strong inventory reduction and new product launches position the company for 7% revenue and 11% EBITDA growth in H2 2025, driven by new products and a direct sales route in Brazil. Q2 and full-year guidance remain cautious, with tariff and FX headwinds mitigated by cost savings.
-
Q1 performance is strong, with inventory normalization on track in most regions and a reset year expected for 2025. Rynaxypyr innovation and cost reductions position the portfolio for growth in 2026–2027, while a new Brazil market segment and robust product pipeline support long-term expansion.
Fiscal Year 2024
-
2025 is set as a correction year with aggressive inventory reduction, cost-cutting, and strategic investments in new products and sales channels, impacting short-term results but positioning for strong growth in 2026–2027. Growth portfolio and Plant Health are key drivers, while FX and pricing headwinds persist.
-
Post-COVID inventory excess and supply chain shifts led to amplified earnings volatility, but inventory normalization is underway in most regions. New product launches and a shift to advanced formulations are expected to drive multi-billion-dollar growth, while cost reductions and portfolio evolution aim to protect margins as key molecules lose patent protection.
-
Third quarter saw 9% sales and 15% adjusted EBITDA growth, led by new products and North America, while Latin America and Asia faced pricing and inventory challenges. Q4 and 2025 growth will rely on new launches, cost savings, and market normalization.
-
Portfolio expansion with four new molecules and a shift to formulations is underway, supporting growth as IP protection for key products expires. Regional markets are normalizing, with Asia lagging, and new products are expected to drive strong financial performance and improved margins through 2025.
-
Q2 2024 saw modest revenue growth and strong volume gains, offset by lower pricing and a $40M COGS headwind. Guidance for 2024 was reduced due to slower demand recovery, but cost savings and new product launches are expected to drive a strong H2 and 2025, with significant free cash flow improvement.
-
Leadership transition is underway with Pierre Brondeau returning as CEO, ensuring continuity. Inventory normalization and recovery are progressing globally, with strong new product performance and a robust innovation pipeline expected to drive growth through 2033.
-
Leadership transitioned to Pierre Brondeau as CEO, with a focus on stabilizing operations and reaffirming Q2 guidance. Cost-saving initiatives and new product launches are expected to drive growth, while inventory rebalancing and patent strategies aim to sustain margins and profitability.